FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225291785> ?p ?o ?g. }

• W4225291785 abstract "Nigeria's healthcare system capacity to stem the increasing trend in hypertension is limited in coverage, scope and manpower. Use of trained community-based care providers demonstrated to be an effective complement in improving access to, and supporting healthcare delivery has not been adequately examined for hypertension care in Nigeria. This study is proposed to evaluate the effectiveness of using trained community-oriented resource persons (CORPs) to improve hypertension control in Nigeria.An intervention study will be conducted in three states using a mixed method design. First is a baseline survey using a semi-structured pre-tested questionnaire to collect information on demographics, clinical data, knowledge, occurrence and risk factors of hypertension among 1704 adults ≥18 years. Focus group discussions (FGD) and key informant interviews (KII) will be conducted to explore a community's experience of hypertension, challenges with hypertension management and support required to improve control in 10 selected communities in each state. The second is a cluster-randomized controlled trial to evaluate effect of a package on reduction of blood pressure (BP) and prevention of cardiovascular (CVD) risk factors among 200 hypertensive patients to be followed up in intervention and control arms over a 6-month period in each state. The package will include trained CORPs conducting community-based screening of BP and referral, diagnosis confirmation and initial treatment in the health facility, followed by monthly home-based follow-up care and provision of health education on hypertension control and healthy lifestyle enhanced by phone voice message reminders. In the control arm, the usual care (diagnosis, treatment and follow-up care in hospital of a patient's choice) will continue. Third, an endline survey will be conducted in both intervention and control communities to evaluate changes in mean BP, control, knowledge and proportion of other CVD risk factors. In addition, FGD and KII will be used to assess participants' perceived quality and acceptability of the interventions as delivered by CORPs.This research is expected to create awareness, improve knowledge, perception, behaviours, attitude and practices that will reduce hypertension in Nigeria. Advocacy for buy-in and scale up of using CORPs in hypertension care by the government is key if found to be effective.PACTR Registry PACTR202107530985857 . Registered on 26 July 2021." @default.
• W4225291785 created "2022-05-05" @default.
• W4225291785 creator A5000969717 @default.
• W4225291785 creator A5004571772 @default.
• W4225291785 creator A5021065263 @default.
• W4225291785 creator A5022118760 @default.
• W4225291785 creator A5029182112 @default.
• W4225291785 creator A5034526604 @default.
• W4225291785 creator A5035847417 @default.
• W4225291785 creator A5059557658 @default.
• W4225291785 creator A5080576595 @default.
• W4225291785 date "2022-05-02" @default.
• W4225291785 modified "2023-09-26" @default.
• W4225291785 title "Development and evaluation of a package to improve hypertension control in Nigeria [DEPIHCON]: a cluster-randomized controlled trial" @default.
• W4225291785 cites W1489352348 @default.
• W4225291785 cites W1514404275 @default.
• W4225291785 cites W153825505 @default.
• W4225291785 cites W1588373909 @default.
• W4225291785 cites W2023226395 @default.
• W4225291785 cites W2036682250 @default.
• W4225291785 cites W2048007696 @default.
• W4225291785 cites W2067670310 @default.
• W4225291785 cites W2105654771 @default.
• W4225291785 cites W2120131965 @default.
• W4225291785 cites W2122389877 @default.
• W4225291785 cites W2140814697 @default.
• W4225291785 cites W2152781298 @default.
• W4225291785 cites W2154467145 @default.
• W4225291785 cites W2156121263 @default.
• W4225291785 cites W2268817813 @default.
• W4225291785 cites W2349671765 @default.
• W4225291785 cites W2504981678 @default.
• W4225291785 cites W2572331255 @default.
• W4225291785 cites W2583634217 @default.
• W4225291785 cites W2601629309 @default.
• W4225291785 cites W2616261545 @default.
• W4225291785 cites W2726209837 @default.
• W4225291785 cites W2766036170 @default.
• W4225291785 cites W2774469713 @default.
• W4225291785 cites W2790471463 @default.
• W4225291785 cites W2809710353 @default.
• W4225291785 cites W2897531761 @default.
• W4225291785 cites W2901899325 @default.
• W4225291785 cites W2926454436 @default.
• W4225291785 cites W2953520589 @default.
• W4225291785 cites W2967822601 @default.
• W4225291785 cites W3157522282 @default.
• W4225291785 cites W3164570271 @default.
• W4225291785 cites W3164860355 @default.
• W4225291785 cites W4233077376 @default.
• W4225291785 doi "https://doi.org/10.1186/s13063-022-06209-9" @default.
• W4225291785 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35501887" @default.
• W4225291785 hasPublicationYear "2022" @default.
• W4225291785 type Work @default.
• W4225291785 citedByCount "1" @default.
• W4225291785 countsByYear W42252917852023 @default.
• W4225291785 crossrefType "journal-article" @default.
• W4225291785 hasAuthorship W4225291785A5000969717 @default.
• W4225291785 hasAuthorship W4225291785A5004571772 @default.
• W4225291785 hasAuthorship W4225291785A5021065263 @default.
• W4225291785 hasAuthorship W4225291785A5022118760 @default.
• W4225291785 hasAuthorship W4225291785A5029182112 @default.
• W4225291785 hasAuthorship W4225291785A5034526604 @default.
• W4225291785 hasAuthorship W4225291785A5035847417 @default.
• W4225291785 hasAuthorship W4225291785A5059557658 @default.
• W4225291785 hasAuthorship W4225291785A5080576595 @default.
• W4225291785 hasBestOaLocation W42252917851 @default.
• W4225291785 hasConcept C141071460 @default.
• W4225291785 hasConcept C159110408 @default.
• W4225291785 hasConcept C160735492 @default.
• W4225291785 hasConcept C162324750 @default.
• W4225291785 hasConcept C168563851 @default.
• W4225291785 hasConcept C176400912 @default.
• W4225291785 hasConcept C1862650 @default.
• W4225291785 hasConcept C2776135927 @default.
• W4225291785 hasConcept C2780665704 @default.
• W4225291785 hasConcept C50522688 @default.
• W4225291785 hasConcept C512399662 @default.
• W4225291785 hasConcept C71924100 @default.
• W4225291785 hasConceptScore W4225291785C141071460 @default.
• W4225291785 hasConceptScore W4225291785C159110408 @default.
• W4225291785 hasConceptScore W4225291785C160735492 @default.
• W4225291785 hasConceptScore W4225291785C162324750 @default.
• W4225291785 hasConceptScore W4225291785C168563851 @default.
• W4225291785 hasConceptScore W4225291785C176400912 @default.
• W4225291785 hasConceptScore W4225291785C1862650 @default.
• W4225291785 hasConceptScore W4225291785C2776135927 @default.
• W4225291785 hasConceptScore W4225291785C2780665704 @default.
• W4225291785 hasConceptScore W4225291785C50522688 @default.
• W4225291785 hasConceptScore W4225291785C512399662 @default.
• W4225291785 hasConceptScore W4225291785C71924100 @default.
• W4225291785 hasFunder F4320325463 @default.
• W4225291785 hasIssue "1" @default.
• W4225291785 hasLocation W42252917851 @default.
• W4225291785 hasLocation W42252917852 @default.
• W4225291785 hasLocation W42252917853 @default.
• W4225291785 hasOpenAccess W4225291785 @default.
• W4225291785 hasPrimaryLocation W42252917851 @default.
• W4225291785 hasRelatedWork W1965851575 @default.
• W4225291785 hasRelatedWork W2013504325 @default.

• next